HOPEWIND-ELECTRIC
28.5.2024 13:17:33 CEST | Business Wire | Press release
Hopewind (SHANGHAI STOCK EXCHANGE Code: 603063) has been officially nominated for the 2024 Smarter E award for its grid forming capable 385 kW utility-scale string inverter. Selected by jury for the Top 10 short list, makes Hopewind the only Chinese solar inverter manufacturer to reach the finals, highlighting the company's strong R&D capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527117090/en/
Hopewind has been officially nominated for the 2024 Smarter E award (Photo: Business Wire)
“Our nomination for The Smarter E / Intersolar Award 2024 underlines our innovative nature that is core to our DNA,” said Wang Yao, Deputy General Manager of Hopewind.
Also in May, the Q2/2004 Global PV Market Outlook of Bloomberg New Energy Finance (BNEF) selected Hopewind to join its Tier 1 Photovoltaic Inverter Manufacturer list. “Ranking on BNEF’s prestigious Tier 1 list recognizes our financial and business strengths,” added Wang Yao, “and it confirms our strategy to delve deeper into the PV field, working on further innovations and breakthroughs to lead the development of global clean and renewable energy.”
As part of its innovation strategy, Hopewind officially joined the International Solar Energy Research Center Konstanz (ISC), one of world solar leading research institutes in April. Established in 2007, Hopewind was listed on the Shanghai Stock Exchange (Stock code: 603063) in 2017 as a leading innovator in the clean power generation industry, specializing in designing and producing renewable and electrical solutions, including wind power converters, PV inverters, battery storage systems (BESS), SVG, and industry drives with 150 GW+ shipments worldwide and GW production capacities.
Hopewind, participated in the Wingrid project, supported by the Horizon Europe 2020 and facilitated through the DNV Netherlands Laboratory. In 2023, Hopewind’s wind power converter received the world’s first grid forming certificate from DNV, with the 385kW inverter being selected as No.1 powerful solar string inverter by Solarbe Global since February, 2024.
Like in the Kubuqi Desert of Inner Mongolia, the seventh largest desert in China, an impressive transformation is taking place. Beneath over 10 kilometers of photovoltaic (PV) panels, herbs and pasture thrive, while chickens and goats roam and forage, bringing new life to the arid landscape.
The solar energy captured by these panels is converted into clean electricity by Hopewind 5,604 350kW inverters and fed into the power grid.
“This project showcases our corporate vision, which is to become a world-class provider of power conversion and control solutions, creating a more sustainable future for our world," Wang emphasized.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527117090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom